Rochester NY, January 18, 2007- iCardiac Technologies, Inc., a leader in the development of biomarkers and technologies for cardiac safety testing, announced today that it has received the Frost & Sullivan 2006 North America Technology Innovation of the Year Award in the field of Cardiac Safety Analytics. The award recognized iCardiac’s innovative COMPAS software technology platform, which aids in the detection of whether in-development or on-market drugs cause cardiac toxicity. The COMPAS technology was originally developed over a nearly ten-year span at the University of Rochester’s Heart Research Follow-Up Program (HRFUP), a renowned cardiology research center focusing on the ventricular repolarization process of the heart and arrhythmia prediction.
